Company intelligence / Profile preview

River 3Renal

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

River 3Renal is a biotechnology company focused on developing innovative therapies for renal and cardiovascular diseases. The company's primary research centers on the modulation of the sodium-chloride symporter (NCC), a key protein in the kidney responsible for salt reabsorption. By targeting this pathway, River 3Renal aims to provide more effective treatments for chronic kidney disease and hypertension with improved safety profiles compared to traditional diuretics. The company is currently advancing its lead small molecule candidates through pre-clinical development.

Therapeutic areas: CardiovascularNephrology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on River 3Renal.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on River 3Renal.

Explore the full profile